The Medicines Company (NASDAQ:MDCO) Ratings Summary as of Jun 27, 2018

June 27, 2018 - By Mary Bollinger

The Medicines Company (NASDAQ:MDCO) Corporate Logo
Big Money Sentiment decreased to 1.02 in Q1 2018. It has change of 0.23, from 2017Q4’s 1.25. The ratio worsened due to The Medicines Company positioning: 30 sold and 51 reduced. 25 funds took stakes and 58 increased stakes. Investors holded 89.44 million in 2017Q4 but now own 91.05 million shares or 1.80% more.
Retail Bank Of Montreal Can reported 0% of its capital in The Medicines Company (NASDAQ:MDCO). Pinnacle Associates Limited owns 1.10 million shs. Northern Corporation reported 891,626 shs or 0.01% of all its holdings. Vanguard Inc has invested 0.01% of its capital in The Medicines Company (NASDAQ:MDCO). Legal & General Grp Public Ltd holds 0% of its capital in The Medicines Company (NASDAQ:MDCO) for 138,182 shs. Venbio Select Advisor Limited Liability Com invested 2.57% of its capital in The Medicines Company (NASDAQ:MDCO). Pinebridge Invests L P holds 0.05% of its capital in The Medicines Company (NASDAQ:MDCO) for 65,682 shs. Voya Investment Mngmt Ltd Llc invested in 0% or 30,483 shs. Strs Ohio has invested 0% in The Medicines Company (NASDAQ:MDCO). California State Teachers Retirement Sys reported 0.01% in The Medicines Company (NASDAQ:MDCO). Maverick Capital Limited holds 906,251 shs or 0.39% of its capital. State Street accumulated 2.19M shs. Thrivent Fincl For Lutherans reported 0% in The Medicines Company (NASDAQ:MDCO). Great West Life Assurance Can holds 0.01% of its capital in The Medicines Company (NASDAQ:MDCO) for 86,102 shs. Envestnet Asset Mgmt invested in 0% or 1,233 shs.

The Medicines Company registered $1.06 million net activity with 0 insider buys and 3 insider sales since January 16, 2018. On Tuesday, January 16 Shares for $574,200 were sold by KESSLER ARMIN M. Shares for $241,500 were sold by Spigelman Melvin K on Friday, May 25.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Total analysts of 4 have positions in Medicines Co (NASDAQ:MDCO) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 15, 2018 according to StockzIntelligence Inc Medicines Co has 6 analyst reports. In Monday, January 15 report Oppenheimer maintained the stock with “Buy” rating. On Wednesday, June 6 the firm has “Buy” rating by FBR Capital given. On Monday, January 22 the stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Citigroup. In Thursday, February 22 report Oppenheimer maintained the stock with “Hold” rating. On Thursday, March 22 the stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Oppenheimer. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

06/06/2018 Broker: FBR Capital Rating: Buy New Target: $55.0000 Initiate
22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain

Ticker’s shares touched $35.99 during the last trading session after 1.12% change.The Medicines Company has volume of 464,943 shares. Since June 27, 2017 MDCO has declined 16.45% and is downtrending. The stock underperformed the S&P500 by 29.02%.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is valued at $2.65 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news posted briefly go to: Businesswire.com, Investorplace.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Scientific Sessions┬« Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes” posted on June 26, 2018, “20 Massively Underpriced Stocks Wall Street Expects to Soar” on June 25, 2018, “Medicines Co. (MDCO) Highlights New Data from ORION-1 Phase II Trial at ADA 2018 Conference” with a publish date: June 26, 2018, “Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases” and the last “Premarket analyst action – healthcare” with publication date: June 07, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.